<DOC>
	<DOC>NCT00382187</DOC>
	<brief_summary>The present study aims to evaluate safety and immunogenicity of two doses, administered three weeks apart, and a 6 month booster dose, of two influenza vaccines containing 7.5 micrograms or 15 micrograms of H5N1 influenza antigen, and of a non-adjuvanted influenza vaccine containing 15 micrograms of H5N1 influenza antigen, in adults</brief_summary>
	<brief_title>Safety and Immunogenicity of Two Adjuvanted and One Non-adjuvanted H5N1 Influenza Vaccine in Adults</brief_title>
	<detailed_description />
	<mesh_term>Influenza, Human</mesh_term>
	<mesh_term>Influenza in Birds</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>MF59 oil emulsion</mesh_term>
	<criteria>Male and female volunteers 1860 years of age Any autoimmune disease or other serious acute, chronic or progressive disease Hypersensitivity to eggs, chicken protein, chicken feathers, influenza viral protein, neomycin or polymyxin or any other component of the vaccine History of neurological symptoms or signs, or anaphylactic shock following administration of any vaccine Within the past 7 days, they have experienced any acute disease or infections requiring systemic antibiotic or antiviral therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>influenza</keyword>
	<keyword>pandemic influenza</keyword>
	<keyword>influenza vaccine</keyword>
	<keyword>adjuvanted influenza vaccine</keyword>
	<keyword>H5N1 influenza antigen</keyword>
	<keyword>MF59</keyword>
	<keyword>Pandemic influenza disease</keyword>
</DOC>